American Heart Journal
Volume 148, Issue 5 , Pages 747-754, November 2004

Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers☆

  • Sverre E. Kjeldsen, MD, PhD

      Affiliations

    • Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    • Division of Hypertension, University of Michigan, Ann Arbor, Mich, USA
    • Corresponding Author InformationReprint requests: Sverre E. Kjeldsen, MD, PhD, Department of Cardiology, Ullevaal University Hospital, N-0407 Oslo, Norway.
    • ,
  • Stevo Julius, MD, ScD

      Affiliations

    • Division of Hypertension, University of Michigan, Ann Arbor, Mich, USA

Received 6 June 2003; accepted 6 April 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Conflict of Interest Statement: Both authors were in the leadership of both the LIFE study and the VALUE trial.

PII: S0002-8703(04)00290-X

doi:10.1016/j.ahj.2004.04.037

American Heart Journal
Volume 148, Issue 5 , Pages 747-754, November 2004

Article Tools